Serina Therapeutics' SER-252 Gains Momentum for Advanced Parkinson's Treatment
Serina Therapeutics’ SER-252 for advanced Parkinson's gains FDA support for a registrational study via the 505(b)(2) NDA pathway. The POZ Platform enables continuous dopaminergic stimulation, aiming to improve motor fluctuations.